Method of treating polycystic kidney disease

• US 5,929,080 A
• Filed: 04/21/1998
• Issued: 07/27/1999
• Est. Priority Date: 05/06/1997
• Status: Expired due to Fees

• Current Assignee: Wyeth Holdings Corporation (Pfizer Inc.)
• Original Assignee: American Cyanamid Co (Pfizer Inc.)
• Inventors: Frost, Philip
• Primary Examiner(s): JORDAN, KIMBERLY R
• Application Number:
  US09/063,452
• Time in Patent Office: 462 Days
• Field of Search: 514/259
• US Class Current: 514/266.4
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

This invention provides a method of treating or inhibiting polycystic kidney disease in a mammal in need thereof which comprises administering to said mammal a compound having the formula ##STR1## wherein: X is phenyl which is optionally substituted;

R and R₁ are each, independently, hydrogen, halogen, alkyl, alkoxy, hydroxy, or trifluoromethyl;

R₂ is hydrogen, alkyl, alkoxy, hydroxy, trifluoromethyl;

Y is a radical selected from the group consisting of ##STR2## R₃ is independently hydrogen, alkyl, carboxy, carboalkoxy, phenyl, or carboalkyl; n=2-4;

or a pharmaceutically acceptable salt thereof, with the proviso that each R₃ of Y may be the same or different.

Claims

1. A method of treating or inhibiting polycystic kidney disease in a mammal in need thereof which comprises administering to said mammal a compound of the formula ##STR10## wherein:

X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, amino, and alkanoylamino of 1-6 carbon atoms;

R and R₁ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, or trifluoromethyl;

R₂ is hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, trifluoromethyl;

Y is a radical selected from the group consisting of ##STR11## R₃ is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, or carboalkyl of 2-7 carbon atoms;

n=2-4;

or a pharmaceutically acceptable salt thereof, with the proviso that each R₃ of Y may be the same or different.

2. The method according to claim 1 wherein R, R₁, and R₂ are hydrogen or a pharmaceutically acceptable salt thereof.

3. The method according to claim 2 wherein X is unsubstituted or substituted with halogen or alkyl of 1-6 carbon atoms.

4. The method according to claim 1 in which N- 4- (3-Bromophenyl)amino!-6-quinazolinyl!-2-butynamide or a pharmaceutically acceptable salt thereof is administered.

5. The method according to claim 1 in which N- 4- (3-Bromophenyl)amino!-6-quinazolinyl!-2-methyl-2-propenamide or a pharmaceutically acceptable salt thereof is administered.

6. The method according to claim 1 in which N- 4- (3-Bromophenyl)amino!-6-quinazolinyl!-2,4-hexadienamide or a pharmaceutically acceptable salt thereof is administered.

7. The method according to claim 1 in which N- 4- (3-Bromophenyl)amino!-6-quinazolinyl!-(E)-2-butenarnide or a pharmaceutically acceptable salt thereof is administered.

8. The method according to claim 1 in which N- 4- (3-Bromophenyl)amino!-6-quinazolinyl!-3-methyl-2-butenamide or a pharmaceutically acceptable salt thereof is administered.

9. The method according to claim 1 in which 4- 4- (3-Bromophenyl)amino!-6-quinazolinyl!amino!-4-oxo-(Z)-2-butenoic acid or a pharmaceutically acceptable salt thereof is administered.

10. The method according to claim 1 in which 4- 4- (3-Bromophenyl)amino!-6-quinazolinyl!amino!-4-oxo-(E)-2-butenoic acid or a pharmaceutically acceptable salt thereof is administered.

11. The method according to claim 1 in which 4- 4- (3-Bromophenyl)amino!-6-quinazolinyl!amino!-4-oxo-(E)-2-butenoic acid, ethyl ester or a pharmaceutically acceptable salt thereof is administered.

12. The method according to claim 1 in which N- 4- (3-bromophenyl)amino!-6-quinazolinyl!-2-cyclopentenamide or a pharmaceutically acceptable salt thereof is administered.

13. The method according to claim 1 in which N- 4- (3-Bromophenyl)amino!-6-quinazolinyl!-2-propenamide or a pharmaceutically acceptable salt thereof is administered.

14. The method according to claim 1 in which N- 4- (3-bromophenyl)amino!-6-quinazolinyl!-(3-phenyl-2-propynamide) or a pharmaceutically acceptable salt thereof is administered.